Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in japanese patients with stable schizophrenia

Journal of Clinical Psychopharmacology

Volumn 31, Issue 4, 2011, Pages 526-528

  Suzuki, Yuatro ^a   Sugai, Takuro ^a   Ono, Shin ^a   Sawamura, Kazushi ^a   Fukui, Naoki ^a   Watanabe, Junzo ^a   Tsuneyama, Nobuto ^a   Someya, Toshiyuki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; PLACEBO;

ADULT; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; JAPANESE; LETTER; METABOLIC PARAMETERS; OUTPATIENT; PRIORITY JOURNAL; QT INTERVAL; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BENZODIAZEPINES; DRUG SUBSTITUTION; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79960594907     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318221e80d     Document Type: Letter

References (12)

1. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther. 2010;32(suppl 1):S3-S20.
2. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and safety in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123-136. (Pubitemid 36513927)
3. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006;189:259-266. (Pubitemid 44691547)
4. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64:1048-1056. (Pubitemid 37158250)
5. Yerrabolu M, Prabhudesai S, Tawam M, et al. Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis. 2000;2:10-12.
6. Dickson RA, GlazerWM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35(suppl):S75-S86. (Pubitemid 29133028)
7. Osuntokun OO, Millen B, Xu WI, et al. Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. J Psychopharmacol. 2011;25:630-638.
8. Hanssens L, van Winkel R, Wampers M, et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res. 2008;106:308-314.
9. Birkenaes AB, Birkeland KI, Friis S, et al. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions. J Clin Psychopharmacol. 2009;29:109-116.
10. Baptista T, Dávila A, El Fakih Y, et al. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol. 2007;22:205-211. (Pubitemid 46801943)
11. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164:1404-1410. (Pubitemid 47461141)
12. Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2010; [Epub ahead of print].